014950.KQ Samik Pharm.
- Market cap
- KRW 71.3B
- P/E
- -
- P/B
- 0.98x
- ROE
- 3.2%
- Dividend yield
- 0.40%
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 014950.KQ undervalued?
Graham numberThe Graham number of Samik Pharm. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Samik Pharm. fundamental analysis
5 of 22 checks passedROE 0/2
Low return on equity (3.2%), below 10%.
ROA 1/1
Return on assets (2.7%) is above the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-116.7%) is below the industry median (4.8%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.0x) is below the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (0.4%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Samik Pharm. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Samik Pharm.
Samik Pharmaceutical Company LTD. develops and manufactures pharmaceuticals. The company offers oral therapeutic pharmaceuticals. It also provides drug compounds, drug delivery systems, drug repositioning, and reinforcement of biopharmaceuticals. The company was founded in 1973 and is based in Seoul, South Korea.
Full company profileSamik Pharm. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Samik Pharm. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | - | 60.0B | 62.4B |
| Gross Profit | - | 42.4B | 43.1B |
| Operating Income | 3.68B | 3.27B | 1.40B |
| EBITDA | - | 1.45B | 3.43B |
| Net Income | 3.52B | -755M | 2.32B |
| EPS | 493 | -82 | 252 |
| Balance Sheet | |||
| Total Assets | - | 85.2B | 86.7B |
| Total Liabilities | - | 16.2B | 14.0B |
| Shareholders' Equity | 52.0B | 69.0B | 72.8B |
| Cash & Short-term Investments | - | 5.22B | 7.45B |
| Cash Flow | |||
| Operating Cash Flow | - | 2.08B | 2.10B |
| Capital Expenditure | 0.00 | 3.43B | 1.93B |
| Free Cash Flow | - | -1.35B | 177M |
| Ratios | |||
| ROE | 6.8% | -1.1% | 3.2% |
| ROA | - | -0.9% | 2.7% |
| Net Profit Margin | - | -1.3% | 3.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Samik Pharm. dividends
- Dividend yield
- 0.40%
- Forward dividend
- 40.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 286M | 31 | - |
| 2024 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Samik Pharm.
- Insiders 59.51%
- Institutions 0.00%
- Public & others 40.49%
- Shares outstanding 10.1M
- Free float 3.93M
Samik Pharm. company profile
- Company name
- Samik Pharm.
- Ticker
- 014950.KQ
- ISIN
- KR7014950000
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 15th floor A Tower, Seoul, South Korea, 05836
- Phone
- 82 2 928 0661
- Website
- samik.co.kr
About Samik Pharm.
Samik Pharmaceutical Company LTD. develops and manufactures pharmaceuticals. The company offers oral therapeutic pharmaceuticals. It also provides drug compounds, drug delivery systems, drug repositioning, and reinforcement of biopharmaceuticals. The company was founded in 1973 and is based in Seoul, South Korea.
Samik Pharm. management
3- Choong-Hwan LeeCEO & Chairman
- Young Ee KwonCEO, CTO & Director
- Yong-seok LeeVP & Director